New York (dpa-AFX)-The US exchanges were difficult on Tuesday with a continuation of their latest recreational course. In the service sector, the mood had been unexpectedly clouded in July. This seemed to slow down the indices after the data has been published.
The Dow Jones Industrial then climbed something again and recently noted 0.12 percent higher to 44,225 points. The Nasdaq 100 dominated by technology values lost 0.30 percent to 23,120 points. The S&P 500 market width gave up 0.14 percent to 6,321 points.
With regard to the Monetary policy The US Federal Reserve would be reinforced the already pronounced expectations of loosening in September and the further year, Helaba said with a view to data from the service sector. The FED faces challenges, the experts from Capital Economics commented on the further increased indicator of paid prices.
The interest -reduction fantasy hardly brought the courses because investors focused on the declining economy. The economic worries would be larger, the Helaba continued. Last Friday, a disappointing US labor market report had already fueled the concerns about a cooling economy and sent the stock market indices on a descent, from which they had recovered a bit on Monday.
Palantir won 7.6 percent on Tuesday. The provider of software for analyzing large amounts of data presented strong figures for the second quarter thanks to strong business in connection with “artificial intelligence”. Sales rose by 48 percent to a good one billion US dollars in the year.
Pfizer (Pfizer) attracted 4.8 percent. Despite the price pressure of the US government and the customs dispute, the pharmaceutical company raised his annual profit forecast.
The Dow Group Caterpillar, on the other hand, disappointed with its win in the second quarter. Running prices had borrowed the manufacturer of construction machines and engines. The titles with minus 0.7 percent have not been able to build on their steep price rally since the beginning of April.
The shares of the corporations Hims & Hers Health (Himsher’s Health) and Vertex (Vertex Pharmaceuticals) record stronger losses. The telemedicine company disappointed with its quarterly turnover, whereupon the shares recently fell by 7.9 percent. At the Biopharma company Vertex (Vertex Pharmaceuticals), a skeptical assessment by the US Health Authority FDA was not well received by the Journavx pain reliever. The stocks broke up by almost 19 percent./Ajx/he